Which returned more over the last year, IBB or IGIB?

In the year to Sep 12, 2026, with distributions reinvested, IBB returned +41.5% and IGIB returned −1.0%, so IBB returned more. One year is one year; the longer windows are in the table.

Which is cheaper, IBB or IGIB?

IBB charges 0.44% a year and IGIB charges 0.04%, so IGIB is cheaper. Fees come from each fund's prospectus.

Data as of Sep 12, 2026. Both funds on the fields they both publish, from the same sources.

ETFIQetfiq.com · independent ETF data

IBB vs IGIB: how they differ

IBB and IGIB hold 0% of their weight in the same names, and IBB returned more over the year.

iShares Biotechnology ETF and iShares 5-10 Year Investment Grade Corporate Bond ETF.

What they hold in common

By the books each fund has filed, IBB and IGIB hold 0% of their money in the same securities at the same weight.

Largest positions each one holds and the other does not
Only in IBB	Only in IGIB
Vertex Pharmaceuticals, Inc. 8.09%	META PLATFORMS INC 0.24%
Amgen, Inc. 7.84%	AMAZON.COM INC 0.23%
Gilead Sciences, Inc. 6.85%	ANHEUSER-BUSCH CO/INBEV 0.20%
Regeneron Pharmaceuticals, Inc. 4.91%	BANK OF AMERICA CORP 0.20%
Argenx SE 3.76%	BANK OF AMERICA CORP 0.20%
Alnylam Pharmaceuticals, Inc. 3.12%	BANK OF AMERICA CORP 0.20%
Natera, Inc. 2.89%	MARS INC 0.19%
Revolution Medicines, Inc. 2.78%	PFIZER INVESTMENT ENTER 0.19%

Weight overlap is an ETFIQ calculation: for every security both funds hold, the smaller of the two weights, summed. Above 50%, holding both is close to holding one of them twice. Holdings dated Jun 30, 2026 and May 31, 2026.

IBB and IGIB on the fields both publish, as of Sep 12, 2026. Source: ETFIQ.
	IBB iShares Biotechnology ETF	IGIB iShares 5-10 Year Investment Grade Corporate Bond ETF
Where it sits	Core index fund	Core index fund
Issuer	iShares	iShares
What it is	Biotechnology	5-10 Year Investment Grade Corporate Bond
Total return, 1 year	+41.5%	−1.0%
S&P 500 over the same days	+17.5%	+17.5%
Gap to the S&P 500	+24.0 pts	−18.5 pts
Expense ratio	0.44%	0.04%
Holdings	248	2988

IBB in plain words

IBB is an index equity fund tracking the Biotechnology. Over the year to Sep 11, 2026 it returned +41.5% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.44% a year. By its holdings filed for Jun 30, 2026, 36% of the fund by weight is stocks the S&P 500 also holds, across 248 positions, with the top ten at 44.8%. It sat 6.5% below its high of Aug 19, 2026 on Sep 11, 2026.

IGIB in plain words

IGIB is a bond fund tracking the 5-10 Year Investment Grade Corporate Bond. Over the year to Sep 11, 2026 it returned −1.0% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.04% a year. It sat 3.3% below its high of Feb 27, 2026 on Sep 11, 2026.

Questions people ask

Which returned more over the last year, IBB or IGIB?: In the year to Sep 12, 2026, with distributions reinvested, IBB returned +41.5% and IGIB returned −1.0%, so IBB returned more. One year is one year; the longer windows are in the table.
Which is cheaper, IBB or IGIB?: IBB charges 0.44% a year and IGIB charges 0.04%, so IGIB is cheaper. Fees come from each fund's prospectus.

Other comparisons

Where to next

Where these figures came from

ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.

IBB against IGIB, ETFIQ, data as of Sep 12, 2026. Every figure is arithmetic on a named public source; the method is at etfiq.com/methodology. A comparison is not a recommendation.

Cite this page. ETFIQ, IBB against IGIB, data as of Sep 12, 2026. https://etfiq.com/compare/any/IBB-IGIB Free to use with attribution; the underlying files are at Open data.

A comparison is not a recommendation. Standards and sources